Daniel Willem Hommes MD PhD
Professor, Medicine, University of California Los Angeles David Geffen SOM
Join to View Full Profile
200 Medical Plz365 ALos Angeles, CA 90095
Phone+1 310-825-1597
Fax+1 310-794-9718
Dr. Hommes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Amsterdam Faculty of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 2011 - 2019
Clinical Trials
- Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease Start of enrollment: 2010 Jun 01
- Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment Start of enrollment: 2014 Feb 01
- OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome Start of enrollment: 2017 Feb 28
Publications & Presentations
PubMed
- 4 citationsEarly Detection of Advanced Adenomas and Colorectal Carcinoma by Serum Glycoproteome Profiling.Khushbu Desai, Samir Gupta, Folasade P May, Gege Xu, Aasma Shaukat
Gastroenterology. 2024-01-01 - 2 citationsWarning Signs From the Crypt: Aberrant Protein Glycosylation Marks Opportunities for Early Colorectal Cancer Detection.Dharini Chandrasekar, Christina Guerrier, Frederico Alisson-Silva, Chirag Dhar, Tomislav Caval
Clinical and Translational Gastroenterology. 2023-07-01 - 13 citationsArtificial Intelligence for Inflammatory Bowel Diseases (IBD); Accurately Predicting Adverse Outcomes Using Machine Learning.Aria Zand, Zack Stokes, Arjun Sharma, Welmoed K van Deen, Daniel Hommes
Digestive Diseases and Sciences. 2022-10-01
Press Mentions
InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023April 19th, 2023- DEARhealth Becomes One of the World’s First Companies to Obtain CE-Marking According to New European Union Medical Device Regulation (MDR)June 10th, 2021
- DEARhealth Recruits Senior Executives to Accelerate GrowthMarch 30th, 2021
Other Languages
- Dutch, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
